AMENDMENTS TO THE SPECIFICATION:

Please amend the specification as follows:

On page 4, delete the entire paragraph beginning on line 3.

In one embodiment, the antibody is produced by a hybridoma selected from the group consisting of: ATCC Accession No. _____ (hybridoma ____), ATCC Accession No. _____ (hybridoma ____).

On page 4, replace the paragraph beginning on line 27, with the following amended paragraph:

In yet another embodiment, the invention pertains to a method of modulating the immune response comprising contacting a cell with an antibody specifically reactive with CTLA4, wherein the antibody is produced by a hybridoma selected from the group consisting of: ATCC Accession No. _____ (hybridoma ____), ATCC Accession No. _____ (hybridoma _____), ATCC Accession No. _____ (hybridoma _____), ATCC Accession No. _____ (hybridoma _____). In another embodiment, the antibody comprises an amino acid sequence shown in SEQ ID NO:8. In still another embodiment, the antibody comprises an amino acid sequence shown in SEQ ID NO:10.

On page 28, replace the paragraph beginning on line 8, with the following amended paragraph:

Preferred antibodies are anti-human CTLA4 monoclonal antibody numbers 25, 26, 27, 29, 33, 34, 35, 36, or 38 described herein. These antibodies were determined to be of the IgG1 isotype. The preparation and characterization of these antibodies is described in detail in the appended examples. Hybridoma cells were deposited with the American Type Culture Collection, which meets the requirements of the Budapest Treaty, on as ATCC Accession No. _____ (antibody 25 or hybridoma ____), ATCC Accession No. _____ (antibody 26 or hybridoma ____), ATCC Accession No. _____ (antibody 27 or hybridoma ____), ATCC Accession No. _____ (antibody 33 or hybridoma ____), ATCC Accession No. _____ (antibody 34 or hybridoma ____), ATCC Accession No. _____ (antibody 35 or hybridoma _____), ATCC Accession No. _____ (antibody 36 or hybridoma _____), and ATCC Accession No. _____ (antibody 38 or hybridoma _____), and ATCC Accession No. _____ (antibody 38 or hybridoma ______).